Trials / Not Yet Recruiting
Not Yet RecruitingNCT07263295
Evaluation of Diaphragmatic Function After Interscalene Block With Liposomal Bupivacaine
Evaluation of Diaphragmatic Function After Interscalene Brachial Plexus Block With Liposomal Bupivacaine: A Cohort Study
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluation the effects of Liposomal Bupivacaine on diaphragmatic function in patients undergoing upper limb surgery who receive Interscalene Brachial Plexus Block. A total of 120 eligible patients will be enrolled and divided into two groups: Group A will receive 20ml of 0.5% Hydrochloride Bupivacaine , while Group B will receive 10ml of 0.5% Hydrochloride Bupivacaine plus 10ml of Liposomal Bupivacaine. Assessments of diaphragmatic function, pulmonary function, and pain intensity will be performed before the block and at different time points after the block, with follow-up for adverse events. The study is scheduled to run from September 2025 to September 2026, with strict adherence to privacy protection and ethical guidelines.
Conditions
- Diaphragmatic Function
- Metacarpal Fracture
- Radius Fracture
- Peripheral Nerve Neurolysis
- Chronic Ulcer
- Upper Extremity Ligament Injury
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.5% Hydrochloride Bupivacaine 20ml | 0.5% Hydrochloride Bupivacaine 20ml for ISBPB |
| DRUG | 0.5% Hydrochloride Bupivacaine 10ml | 0.5% Hydrochloride Bupivacaine 10ml for ISBPB |
| DRUG | Liposomal Bupivacaine 10mL | Liposomal Bupivacaine 10mL for ISBPB |
Timeline
- Start date
- 2025-12-05
- Primary completion
- 2026-09-20
- Completion
- 2026-12-20
- First posted
- 2025-12-04
- Last updated
- 2025-12-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07263295. Inclusion in this directory is not an endorsement.